Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy (NCT04283539) | National Jewish Health | 2020-09-23 |
Track Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control automatically
Every clearance here is in the API, with alerts when new ones post.